Enlivex Ltd ENLV Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.21 down $0.02, 8.56% at close Oct 16
Last close · Previous close $0.22
- Market cap
- At the Oct 16 close
- Dividend yield
- NoneLast 12 months
Price chart
$0.21down $0.02, 8.56%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.22Oct 15
- Volume479.69KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.41MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.20 to $27.15; now $0.21
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ENLV trailed the S&P 500 in all 7 periods.
| Period | ENLV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ENLV: down 74.7% S&P 500: up 1.5% | ENLV trailed the S&P 500 by 76.2 percentage points Trailed |
| 3M | ENLV: down 95.7% S&P 500: up 1.9% | ENLV trailed the S&P 500 by 97.6 percentage points Trailed |
| YTD | ENLV: down 98.1% S&P 500: up 12.8% | ENLV trailed the S&P 500 by 110.9 percentage points Trailed |
| 1Y | ENLV: down 98.8% S&P 500: up 16.8% | ENLV trailed the S&P 500 by 115.6 percentage points Trailed |
| Long term | ||
| 3Y | ENLV: down 99.0% S&P 500: up 81.5% −78.6% vs +22.0% a year | ENLV trailed the S&P 500 by 180.5 percentage points Trailed |
| 5Y | ENLV: down 99.9% S&P 500: up 83.1% −72.9% vs +12.9% a year | ENLV trailed the S&P 500 by 183.0 percentage points Trailed |
| 10Y | ENLV: down 100.0% S&P 500: up 319.6% −57.2% vs +15.4% a year | ENLV trailed the S&P 500 by 419.6 percentage points Trailed |
$10,000 invested in ENLV 10 years ago (Oct 14, 2016) would be worth about $2 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
ENLV trailed the S&P 500 in all 7 periods.
| Period | ENLV and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ENLV: down 74.7% S&P 500: up 1.2% | ENLV trailed the S&P 500 by 75.9 percentage points Trailed |
| 3M | ENLV: down 95.7% S&P 500: up 1.7% | ENLV trailed the S&P 500 by 97.4 percentage points Trailed |
| YTD | ENLV: down 98.1% S&P 500: up 11.9% | ENLV trailed the S&P 500 by 110.0 percentage points Trailed |
| 1Y | ENLV: down 98.8% S&P 500: up 15.5% | ENLV trailed the S&P 500 by 114.3 percentage points Trailed |
| Long term | ||
| 3Y | ENLV: down 99.0% S&P 500: up 75.0% −78.6% vs +20.5% a year | ENLV trailed the S&P 500 by 174.0 percentage points Trailed |
| 5Y | ENLV: down 99.9% S&P 500: up 71.2% −72.9% vs +11.4% a year | ENLV trailed the S&P 500 by 171.1 percentage points Trailed |
| 10Y | ENLV: down 100.0% S&P 500: up 258.1% −57.2% vs +13.6% a year | ENLV trailed the S&P 500 by 358.1 percentage points Trailed |
$10,000 invested in ENLV 10 years ago (Oct 14, 2016) would be worth about $2 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$5,874.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jul 31, 2014.
Stock splits
3
Latest: 1-for-15 on . Share counts adjust after each split.
All 3 splits
- 1-for-15
- 1-for-8
- 1-for-5
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026. 12-month figures aren’t available until four quarters are reported.
Revenue and net income
12-month figures aren’t available until four quarters are reported.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY24 (Jun 30, 2024) | $0.00 | −$3.10M | Paused See the note under the price. |
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$2.60M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$5.18M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$3.45M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$1.87M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$2.21M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | $1.24B | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | $1.89B | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$14.47M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$31.06M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$29.07M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$15.01M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | $1.24B | Paused See the note under the price. |
Margins
- Gross
- Operating
- Net
The lines show each quarter. What margins tell you
Cash flow
12-month figures aren’t available until four quarters are reported.
Shareholder returns
12-month figures aren’t available until four quarters are reported.
Balance sheet
- $4.89BAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$17.25MAs of Jun 30, 2026
- Net cash$4.88BAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 119.39As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
12-month figures aren’t available until four quarters are reported.
About Enlivex Ltd
Bio Blast Pharma Ltd., a development stage biopharmaceutical company, focuses on the identification, licensing, acquisition, development, and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The company develops Cabaletta, which is in Phase II/III clinical trials for the treatment of oculopharyngeal muscular dystrophy; and Phase II clinical trials for the treatment of spinocerebellar ataxia type 3, as well as in preclinical studies for the treatment of spinobulbar muscular atrophy. Its preclinical development stage product candidates comprise BBrm1 for spinal muscular atrophy; BB-FA for the treatment of friedrichs ataxia; and BB-OTC for ornithine transcarbamylase deficiency. Bio Blast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Israel
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ENLV news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ENLV stock FAQ
What is ENLV stock’s price today?
Enlivex (ENLV) traded at $0.21 at the close on , down $0.02 (8.56%) from the previous close of $0.22. Over the past 52 weeks it has traded between $0.20 and $27.15.
If you invested $1,000 in ENLV 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ENLV on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $1 if invested five years ago and $12 if invested one year ago. Past performance doesn’t predict future returns.
Does ENLV pay a dividend?
Enlivex hasn’t paid a dividend in the last twelve months.
What is ENLV’s 52-week high and low?
Over the past 52 weeks ENLV has traded as low as $0.20 and as high as $27.15. At $0.21 at the close on , it is 99.2% below that high and 0.2% above the low.
What is ENLV’s all-time high?
ENLV’s highest closing price was $5,874.00 on , adjusted for stock splits. At $0.21 at the close on , it is 100.0% below that record.
Has ENLV stock ever split?
Yes, three times: 1-for-5 on ; 1-for-8 on ; 1-for-15 on .
How has ENLV stock performed?
Including dividends and measured to the close on , ENLV has returned −98.1% so far this year and −98.8% over the past year, and −99.9% over five years (−72.9% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Enlivex in?
Enlivex is in the Healthcare sector and the Biotechnology industry, and is headquartered in Israel.
What exchange does ENLV trade on?
Enlivex trades on the Nasdaq under the ticker symbol ENLV. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.